Pemlimogene Merolisbac

Pemlimogene Merolisbac Uses, Dosage, Side Effects, Food Interaction and all others data.

Pemlimogene Merolisbac is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung).

Trade Name	Pemlimogene Merolisbac
Generic	Pemlimogene merolisbac
Pemlimogene merolisbac Other Names	Ladd listeria monocytogenes jnj-64041757, Live-attenuated listeria monocytogenes encoding egfrviii-mesothelin vaccine jnj-64041757, Pemlimogene merolisbac, Recombinant live-attenuated double-deleted (ladd) strain of listeria monocytogenes (lm .delta.acta/.delta.inlb) expressing a fusion protein comprising the n-terminal 100 amino acids of the lm acta protein (actan100), 5 tandem copies of a 21 amino acid fr
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Innovators Monograph

You find simplified version here Pemlimogene Merolisbac